Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, Roberta, Damiano, Vincenzo, Formisano, Luigi, Nappi, Lucia, Marciano, Roberta, Veneziani, Bianca Maria, De Placido, Sabino, Bianco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782521/
https://www.ncbi.nlm.nih.gov/pubmed/24083076
http://dx.doi.org/10.4161/onci.25123
Descripción
Sumario:The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.

Ejemplares similares